Darwin $120 mil. acquisition by Chiroscience combines genomic, chiral technologies.
Executive Summary
DARWIN $120 MIL. ACQUISITION BY CHIROSCIENCE WILL COMBINE GENOMIC AND CHIRAL technologies within the Cambridge, U.K.-based drug discovery company. According to the terms of a conditional merger agreement announced Nov. 20, Chiroscience will issue to Darwin Molecular shareholders between 17.4 mil. and 21.3 mil. shares depending on the market price of Chiroscience's shares over a period of 10 days ending Dec. 16.